These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38613908)

  • 1. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology.
    Kubo T; Sunami K; Koyama T; Kitami M; Fujiwara Y; Kondo S; Yonemori K; Noguchi E; Morizane C; Goto Y; Maejima A; Iwasa S; Hamaguchi T; Kawai A; Namikawa K; Arakawa A; Sugiyama M; Ohno M; Yoshida T; Hiraoka N; Yoshida A; Yoshida M; Nishino T; Furukawa E; Narushima D; Nagai M; Kato M; Ichikawa H; Fujiwara Y; Kohno T; Yamamoto N
    ESMO Open; 2024 Apr; 9(4):102981. PubMed ID: 38613908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of barriers to implementation of precision oncology in patients with rare cancers.
    Takamizawa S; Koyama T; Sunami K; Sudo K; Hirata M; Kubo T; Tao K; Cho H; Narita Y; Kato K; Yamazaki N; Ohe Y; Okusaka T; Matsui Y; Ogawa C; Yonemori K; Yamamoto N
    Cancer Sci; 2024 Jun; 115(6):2023-2035. PubMed ID: 38538548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
    Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
    J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.
    Ibrahim T; Ahmadie A; Rassy E; Karak FE; Hanna C; Farhat F; Kattan J; Ghosn M
    Bull Cancer; 2020 Apr; 107(4):410-416. PubMed ID: 32145962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world assessment of comprehensive genome profiling impact on clinical outcomes: A single-institution study in Japan.
    Kunimasa K; Sugimoto N; Yamasaki T; Kukita Y; Fujisawa F; Inoue T; Yamaguchi Y; Kitasaka M; Sakai D; Honma K; Wakamatsu T; Yamamoto S; Hayashi T; Mabuchi S; Okuno J; Kawamura T; Kai Y; Urabe M; Nishimura K
    Cancer Med; 2024 Sep; 13(18):e70249. PubMed ID: 39315676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
    Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
    JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First report: PLATFORM study for precision treatment of rare tumors in China.
    Zhou J; Ma P; Jiang Y; Xing S; Wang S; Li N
    Cancer Lett; 2024 Aug; 597():217021. PubMed ID: 38876388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
    Radovich M; Kiel PJ; Nance SM; Niland EE; Parsley ME; Ferguson ME; Jiang G; Ammakkanavar NR; Einhorn LH; Cheng L; Nassiri M; Davidson DD; Rushing DA; Loehrer PJ; Pili R; Hanna N; Callaghan JT; Skaar TC; Helft PR; Shahda S; O'Neil BH; Schneider BP
    Oncotarget; 2016 Aug; 7(35):56491-56500. PubMed ID: 27447854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Availability of genome-matched therapy based on clinical practice.
    Hayashi N; Mori S; Ohmoto A; Fukada I; Yamazaki M; Hosonaga M; Wang X; Ueki A; Kiyotani K; Tonooka A; Takeuchi K; Takahashi S
    Int J Clin Oncol; 2024 Jul; 29(7):964-971. PubMed ID: 38668785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of Precision Oncology Using Cancer Genomic Profiling for Head and Neck Malignancies.
    Matsuo M; Hashimoto K; Kogo R; Jiromaru R; Hongo T; Manako T; Nakagawa T
    In Vivo; 2023; 37(5):2147-2154. PubMed ID: 37652518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
    Ida H; Koyama T; Mizuno T; Sunami K; Kubo T; Sudo K; Tao K; Hirata M; Yonemori K; Kato K; Okusaka T; Ohe Y; Matsui Y; Yamazaki N; Ogawa C; Kawai A; Narita Y; Esaki M; Yamamoto N
    Cancer Sci; 2022 Dec; 113(12):4300-4310. PubMed ID: 36106376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of psychological distress and associated factors among patients undergoing comprehensive genomic profiling testing: protocol for a multicentre, prospective, observational study.
    Matsuoka A; Fujimori M; Koyama T; Sato A; Mori K; Hirata M; Tanabe N; Nakachi K; Kato S; Okamoto H; Ogawa K; Komatsu H; Iwasaku M; Miyaji T; Uchitomi Y
    BMJ Open; 2023 Nov; 13(11):e072472. PubMed ID: 37996226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronological improvement in precision oncology implementation in Japan.
    Sunami K; Naito Y; Komine K; Amano T; Ennishi D; Imai M; Kage H; Kanai M; Kenmotsu H; Koyama T; Maeda T; Morita S; Sakai D; Kohsaka S; Tsuchihara K; Saigusa Y; Yoshino T
    Cancer Sci; 2022 Nov; 113(11):3995-4000. PubMed ID: 35976133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.
    Kondo T; Matsubara J; Quy PN; Fukuyama K; Nomura M; Funakoshi T; Doi K; Sakamori Y; Yoshioka M; Yokoyama A; Tamaoki M; Kou T; Hirohashi K; Yamada A; Yamamoto Y; Minamiguchi S; Nishigaki M; Yamada T; Kanai M; Matsumoto S; Muto M
    Cancer Sci; 2021 Jan; 112(1):296-304. PubMed ID: 33007138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
    Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
    Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current Status and Prospects of the Comprehensive Cancer Genome Profiling].
    Imoto I; Fukue M; Takaiso N
    Gan To Kagaku Ryoho; 2021 Jan; 48(1):7-11. PubMed ID: 33468714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
    Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
    Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences.
    Tóth E; Kürönya Z; Soós E; Pintér T; Butz H; Horváth Z; Csernák E; Grolmusz VK; Székely J; Straussz T; Lövey J; Jánvári L; Báthory-Fülöp L; Nagy P; Polgár C; Patócs A
    Acta Oncol; 2024 Jun; 63():433-440. PubMed ID: 38881341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer.
    Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L
    JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
    Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
    J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.